Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  talazoparib
Find trials that include:  Any drugs shown
Results 1-12 of 12 for your search:
Start Over
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 673-301, NCI-2014-00659, U1111-1155-7579, NCT01945775
PARP inhibitor BMN-673 in Treating Patients with Advanced Solid Tumors and BRCA Mutations
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-C-0015, NCI-2013-02371, 09-25-0099, 140015, P131220, P9510_A08PAMDREVW01, 9510, NCT01989546
BMN-673 and Temozolomide in Treating Younger Patients with Refractory or Recurrent Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months to 30 years
Trial IDs: ADVL1411, NCI-2014-00804, NCT02116777
BMN-673 before Standard Therapy in Treating Patients with Invasive, BRCA-Mutated Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0045, NCI-2015-00335, NCT02282345
PARP Inhibitor BMN-673 in Treating Patients with Recurrent, Locally Advanced or Metastatic Tumors and Alterations in the BRCA or PTEN Genes
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0961, NCI-2014-02494, NCT02286687
Talazoparib in Treating Patients with Recurrent and/or Metastatic Ovarian Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-C-0050, NCI-2014-01288, P131379, 9632, NCT02326844
PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients with Locally Advanced or Metastatic Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TRIO-US GI-07, NCI-2014-00048, 13-001857, NCT02049593
Talazoparib, Carboplatin, and Paclitaxel in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NCI 9782, NCI-2014-02474, 9782, NCT02317874
Talazoparib, Carboplatin, and Paclitaxel in Treating Patients with Advanced Solid Tumors and BRCA Mutations or Triple-Negative Metastatic Breast Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CC #14955, NCI-2015-00713, 130847, 14955, NCT02358200
BMN-673 and Irinotecan Hydrochloride with or without Temozolomide in Treating Younger Patients with Refractory or Recurrent Solid Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 25
Trial IDs: BMNIRN, NCI-2015-00255, NCI-2015-00215, NCT02392793
PARP Inhibitor BMN-673 in Determining Genetic Effects on Disease Response in Patients with Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0474, NCI-2014-02608, NCT02316834
Start Over